logo

Inflarx N.V. (IFRX)



Trade IFRX now with
  Date
  Headline
2/26/2020 7:52:41 AM InflaRx Announces Positive Initial Data From Phase IIa Open Label Study With IFX-1 In Patients Suffering From PG
1/3/2019 8:38:33 AM InflaRx Opens Second U.S.-based Location And The Addition Of New Management Members
12/19/2018 8:36:36 AM InflaRx Gets European Approval To Initiate Phase II Trial With IFX-1 In ANCA-Associated Vasculitis
11/8/2018 3:05:16 AM InflaRx Completes Enrollment In Phase IIb Clinical Trial With Candidate IFX-1 In Hidradenitis Suppurativa
10/30/2018 7:30:30 AM InflaRx Initiates Phase II Clinical Trial With IFX-1 In ANCA-Associated Vasculitis With First Patient Dosing
9/21/2018 8:31:37 AM InflaRx Appoints Jens Holstein To Board Of Directors
8/9/2018 7:12:04 AM InflaRx N.V. Q2 Net Loss Narrows To EUR 2.5 Mln From EUR 4.7 Mln Last Year
6/5/2018 7:34:28 AM InflaRx Opens New Research Facility In Ann Arbor, Michigan
5/8/2018 10:44:25 AM InflaRx N.V. Closes Primary And Secondary Offering Of Common Shares
5/3/2018 8:33:46 PM InflaRx N.V. Announces Pricing Of Primary And Secondary Offering Of Common Shares At $34.00/shr